Researchers from the Perelman School of Medicine at the University of Pennsylvania are developing an experimental mRNA ‘vaccine’ for avian influenza.
An experimental mRNA vaccine against avian influenza virus H5N1 is highly effective in preventing severe illness and death in preclinical models. The vaccine could potentially help manage the outbreak of the H5N1 virus currently circulating in birds and cattle in the United States, and prevent human infections with the virus.
The Penn scientists, in collaboration with mRNA vaccine pioneer Drew Weissman, published their research on May 23, 2024, in Nature Communications. The novel mRNA technology allows for rapid vaccine development, aiding in swift responses to potential pandemics.
Unlike traditional egg-based influenza vaccines, the mRNA vaccine does not require adapting viruses to replicate in fertilized eggs. This advancement streamlines the process of vaccine production and makes it easier to target different strains of influenza viruses. The researchers’ focus on the H5N1 subtype aims to address the potential threat of a human pandemic.
The experimental vaccine generated robust immune responses in animal models, showed long-lasting protection, and increased survival rates following H5N1 infection. These promising results position the mRNA vaccine as a valuable tool against avian influenza outbreaks.
Reports of additional human cases of H5N1 Avian Influenza have sparked preparation efforts by health organizations, highlighting the urgency for effective vaccines. Recognizing this need, Pfizer and Moderna are reportedly exploring mRNA-based avian influenza vaccines in collaboration with the U.S. Department of Health and Human Services.
Efforts to combat bird flu and enhance global health security are underway, leveraging innovative vaccine technologies that have proven successful in addressing emerging viral threats.
